Helix Acquisition CORP Ii 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
BridgeBio Oncology Therapeutics, Inc. reported increased operating expenses and net losses for the second quarter of 2026, driven by expanded research and development activities for its lead product candidates.
BridgeBio Oncology Therapeutics reported a net loss of $42.1 million for Q1 2026, with increased R&D expenses driven by clinical trial activities.
BridgeBio Oncology Therapeutics reports significant cash increase and expanded R&D post-de-SPAC transaction, while net losses widened due to increased operational and clinical development costs.
Helix Acquisition Corp. II reports significant progress on its proposed business combination with BridgeBio Oncology Therapeutics, securing substantial PIPE investments and non-redemption agreements, despite facing a current liquidity deficit and a going concern warning.
Helix Acquisition Corp. II reports a net loss for Q1 2025 as it progresses towards a proposed business combination with BridgeBio Oncology Therapeutics.
Helix Acquisition Corp. II, a special purpose acquisition company, reported a net income of $2.3 million for the quarter ended September 30, 2024, primarily driven by interest income from its trust account.
Helix Acquisition Corp. II reported a net income of $2.2 million for the quarter ended June 30, 2024, primarily driven by interest earned on marketable securities held in trust.
Helix Acquisition Corp. II, a special purpose acquisition company, reported a net income of $1.1 million for the quarter ended March 31, 2024, primarily driven by interest earned on its trust account after its initial public offering.